Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Bowden

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Plos One|October 31, 2012
Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugsRachel Sacks-Davis, Galina Daraganova, Campbell Aitken, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 30, 2016
Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapyLucy Lim, Alexander Thompson, Scott Patterson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 30, 2019
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapseTimothy Papaluca, Marie Sinclair, Paul Gow, et al.
Hepatitis Monthly|February 6, 2014
Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug UsersJacqueline K Flynn, Rachel Sacks-Davis, Peter Higgs, et al.
AIDS (London, England)|July 9, 2009
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individualsGail V Matthews, Eric Seaberg, Gregory J Dore, et al.
Gastroenterology|June 9, 2005
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapyJoseph J Y Sung, May-Ling Wong, Scott Bowden, et al.
Plos One|April 18, 2013
Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individualsGail V Matthews, Rachel J Ali, Anchalee Avihingsanon, et al.
AIDS (London, England)|March 8, 2016
Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversityJennifer Audsley, Stephen J Bent, Margaret Littlejohn, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in ThailandGail V Matthews, Anchalee Avihingsanon, Sharon R Lewin, et al.
Journal of Hepatology|January 27, 2011
Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver diseaseMark D Berzsenyi, David J Woollard, Catriona A McLean, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Plos One|October 31, 2012
Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugsRachel Sacks-Davis, Galina Daraganova, Campbell Aitken, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 30, 2016
Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapyLucy Lim, Alexander Thompson, Scott Patterson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 30, 2019
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapseTimothy Papaluca, Marie Sinclair, Paul Gow, et al.
Hepatitis Monthly|February 6, 2014
Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug UsersJacqueline K Flynn, Rachel Sacks-Davis, Peter Higgs, et al.
AIDS (London, England)|July 9, 2009
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individualsGail V Matthews, Eric Seaberg, Gregory J Dore, et al.
Gastroenterology|June 9, 2005
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapyJoseph J Y Sung, May-Ling Wong, Scott Bowden, et al.
Plos One|April 18, 2013
Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individualsGail V Matthews, Rachel J Ali, Anchalee Avihingsanon, et al.
AIDS (London, England)|March 8, 2016
Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversityJennifer Audsley, Stephen J Bent, Margaret Littlejohn, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in ThailandGail V Matthews, Anchalee Avihingsanon, Sharon R Lewin, et al.
Journal of Hepatology|January 27, 2011
Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver diseaseMark D Berzsenyi, David J Woollard, Catriona A McLean, et al.
Pageof 10